Drug Therapy for Generalized Anxiety Disorder Among the Elderly

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the efficacy of escitalopram (Lexapro®), an anti-anxiety drug, for generalized anxiety disorder (GAD) and the ways genetics affect response to treatment for GAD in elderly individuals.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Mental Health (NIMH); University of Pittsburgh
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Diagnosis of at least moderately severe generalized anxiety disorder (GAD)

Exclusion Criteria:

• Serious suicide risk or psychiatric instability that would affect study participation

• Dementia

• Substance abuse, such as alcoholism, within 6 months prior to study entry

• Diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or bipolar disorder

• Unstable medical conditions that would preclude the use of escitalopram

• Use of certain psychotropics that can not be safely tapered or discontinued for at least 2 weeks prior to and during the study

• Use of neuroleptics that are absorbed over a prolonged period of time within 6 weeks prior to study entry